We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




New Protocol Rapidly Detects Three Legionella Species

By LabMedica International staff writers
Posted on 01 Mar 2016
An innovative protocol has been developed for the detection of the three most prevalent Legionella species, enabling the source of the infection to be located in just eight hours.

The genus Legionella is a pathogenic group of Gram-negative bacteria that includes the species L. More...
pneumophila, causing legionellosis and illnesses caused by Legionella include a pneumonia-type illness called Legionnaires' disease and a mild flu-like illness called Pontiac fever.

Scientists at the Polytechnic University of Valencia (UPV; Spain) initially based their investigation on a study carried out by a Japanese research group aiming to detect as many as four Legionella species simultaneously. However, the UPV team found that this approach was not viable and began devising a protocol for just three species: L. pneumophila (the bacteria responsible for 90% of human Legionella cases, L. micdadei and L. longbeachae. The protocol is considered a breakthrough that relies on the combined use of a multiplex polymerase chain reaction (Multiplex PCR) and pretreatment with propidium monoazide (PMA).

The new protocol brings detection time down from 14 days to just eight hours, which is a marked improvement on the most commonly used detection method. It can also be used successfully in very contaminated samples, where existing methods cannot. Yolanda Moreno Trigo, PhD, the senior scientist on the project, said, “We concentrated the sample, broke the bacteria in order to extract its DNA and then used Multiplex PCR to identify the different Legionella species. The Multiplex PCR amplifies the DNA of the target species, making it easier to identify them. Pretreatment with PMA allows us to immediately discard the DNA of the dead cells, which we are not interested in.”

Related Links:

Polytechnic University of Valencia 



Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
Automated Urinalysis Solution
UN-9000
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A new study identifies distinct metabolomic signatures in maternal blood associated with both the timing and type of early birth (Image credit: iStock)

Maternal Blood Biomarkers Identify Risk of Preterm and Early-Term Birth

Preterm and early-term births can lead to lasting complications because vital organs continue to mature during the final weeks of pregnancy. Babies born too soon face increased risks of breathing difficulties,... Read more

Molecular Diagnostics

view channel
Image: Spatial profiling of muscle-invasive bladder cancer reveals how distinct tumor cell states are organized within individual tumors (Image Credit: Shutterstock)

Spatial Map Guides Treatment Selection in Muscle-Invasive Bladder Cancer

Muscle-invasive bladder cancer is clinically heterogeneous, with patients often responding very differently to therapy. Existing biomarkers do not fully explain these disparities, limiting precision treatment... Read more

Industry

view channel
Image

QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools

QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.